Statins Linked to Greater Atheroma Regression in Women

Share this content:
Statins Linked to Greater Atheroma Regression in Women
Statins Linked to Greater Atheroma Regression in Women

(HealthDay News) — For patients with coronary atheroma, high-intensity statin treatment is associated with greater regression in women than men, according to a study published in JACC: Cardiovascular Imaging.

Rishi Puri, MBBS, from the Cleveland Clinic in Ohio, and colleagues examined sex-related differences in coronary atheroma regression after high-intensity statin treatment. Participants (765 men and 274 women) were treated with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months.

Women were older and more likely to have hypertension; diabetes; and higher LDL cholesterol, HDL cholesterol and C-reactive protein (CRP) levels than men.

Compared with men, at follow-up women had higher HDL (P<.001) and CRP (P<.001) but similar LDL (P=.46) levels.

Women had lower baseline percent atheroma volume (PAV) and total atheroma volume (TAV) than men, but after treatment they demonstrated greater PAV regression (P=.03) and TAV regression (P=.11).

Female sex was independently associated with PAV regression on multivariate analysis (P=.01), and there was a sex-treatment interaction (P=.036). Women achieved greater PAV and TAV regression than men among those with on-treatment LDL levels <70 mg/dL, while there was no difference by sex for those with LDL levels ≥70 mg/dL.

"Women with coronary disease demonstrate greater coronary atheroma regression than men when empirically prescribed guideline-driven potent statin therapy," the researchers wrote.

Several authors disclosed financial ties to pharmaceutical and biotechnology companies, including AstraZeneca, which sponsored the study.

Reference

  1. Puri R et al. J Am Coll Cardiol Img. 2014;doi:10.1016/j.jcmg.2014.04.019.
You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus